Latest Competition News

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

AUCyber Limited reported a 28% revenue decline to $19.98 million in FY26 but cut its net loss by 87% to $4.78 million, driven by exiting low-margin contracts and cost discipline. CEO Joseph Demase now also serves as Chair, steering a strategic shift towards sovereign AI and private cloud solutions.

5G Networks grew revenue by 13% to $71.4 million in FY26, buoyed by enterprise and cloud services including its cyber security acquisition AUCyber. Despite positive underlying EBITDA, net losses widened due to acquisition-related costs as the company pursues integration and data centre growth.

Argent Minerals has secured regulatory approval to launch its first-ever drilling program at the Trunkey Creek Gold Project in NSW, targeting a 4.7km high-grade gold corridor. The initial 1,000m Phase 1 campaign aims to test priority underground targets beneath historic workings.

PeopleIN Limited reversed its earnings decline in FY26, driven by a 74.8% surge in its Engineering, Trades and Labour division amid Queensland’s booming infrastructure projects. The company’s sharper portfolio focus and strengthened balance sheet set the stage for further growth.

AVADA Group lifted revenue by nearly 15% in FY26, driven by Queensland and New South Wales expansion, while managing a $15 million impairment in Victoria that kept the statutory loss steady.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Joyce Corporation Ltd (ASX: JYC) posted a record FY26 profit of $10.8 million, up 32% on normalised NPAT, underpinned by strong growth in its KWB kitchen and wardrobe business and improved Bedshed franchise performance. The company declared a fully franked final dividend of 17 cents, lifting the full-year payout to 30 cents per share.

Michael Hill International delivered a landmark FY26 with record revenue of AU$655.7 million, a 57% jump in comparable EBIT, and reinstated dividends after a strategic turnaround.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Waterco Limited delivered a robust turnaround in FY26 with net profit after tax soaring 61.6% to $15.5 million on modest revenue growth. The company expanded its Swimart franchise, advanced manufacturing insourcing, and boosted dividends to 20 cents per share fully franked.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.